Tower Research Capital LLC TRC grew its position in shares of Novartis AG (NYSE:NVS - Free Report) by 10,877.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 11,197 shares of the company's stock after acquiring an additional 11,095 shares during the period. Tower Research Capital LLC TRC's holdings in Novartis were worth $1,090,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Teachers Retirement System of The State of Kentucky increased its position in Novartis by 7.2% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 246,250 shares of the company's stock worth $23,963,000 after buying an additional 16,450 shares in the last quarter. Seaview Investment Managers LLC grew its position in shares of Novartis by 17.5% during the fourth quarter. Seaview Investment Managers LLC now owns 97,331 shares of the company's stock valued at $9,471,000 after purchasing an additional 14,518 shares in the last quarter. MML Investors Services LLC boosted its stake in Novartis by 15.0% during the fourth quarter. MML Investors Services LLC now owns 148,532 shares of the company's stock valued at $14,454,000 after buying an additional 19,331 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Novartis by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 8,183,855 shares of the company's stock valued at $796,372,000 after acquiring an additional 90,823 shares during the last quarter. Finally, First Trust Advisors LP grew its stake in shares of Novartis by 9.7% in the 4th quarter. First Trust Advisors LP now owns 562,487 shares of the company's stock worth $54,736,000 after buying an additional 49,752 shares in the last quarter. Institutional investors own 13.12% of the company's stock.
Analyst Ratings Changes
NVS has been the subject of several research reports. BNP Paribas raised shares of Novartis to a "strong-buy" rating in a research report on Tuesday, April 15th. Deutsche Bank Aktiengesellschaft upgraded Novartis from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. StockNews.com raised Novartis from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 8th. Barclays reaffirmed an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. Finally, UBS Group restated a "neutral" rating on shares of Novartis in a report on Thursday, February 13th. Three analysts have rated the stock with a sell rating, six have given a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Novartis presently has an average rating of "Hold" and a consensus price target of $123.38.
Check Out Our Latest Stock Report on NVS
Novartis Price Performance
Shares of NYSE:NVS traded up $0.16 on Wednesday, hitting $113.61. The company had a trading volume of 622,137 shares, compared to its average volume of 1,545,968. The company has a current ratio of 1.04, a quick ratio of 0.84 and a debt-to-equity ratio of 0.48. The company has a market cap of $239.99 billion, a PE ratio of 19.34, a PEG ratio of 1.70 and a beta of 0.56. Novartis AG has a 52-week low of $96.06 and a 52-week high of $120.92. The business has a 50 day moving average of $109.91 and a 200 day moving average of $106.13.
Novartis (NYSE:NVS - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $2.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.12 by $0.16. Novartis had a net margin of 23.56% and a return on equity of 37.24%. The firm had revenue of $13.23 billion for the quarter, compared to analyst estimates of $12.92 billion. During the same quarter last year, the business earned $1.80 earnings per share. Novartis's revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts anticipate that Novartis AG will post 8.45 earnings per share for the current fiscal year.
Novartis Dividend Announcement
The firm also recently disclosed a dividend, which was paid on Wednesday, March 12th. Stockholders of record on Wednesday, March 12th were given a dividend of $3.8695 per share. The ex-dividend date was Wednesday, March 12th. Novartis's dividend payout ratio (DPR) is 44.05%.
Novartis Profile
(
Free Report)
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.
Recommended Stories
Before you consider Novartis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.
While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
